Anticholinergic use in children and adolescents after initiation of antipsychotic therapy

Annals of Pharmacotherapy

Volumn 44, Issue 7-8, 2010, Pages 1171-1180

  Hong, Irene Seunghyun ^a   Bishop, Jeffrey R ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Adolescent; Anticholinergic; Antipsychotic; Extrapyramidal symptoms; Pediatric

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; BENZATROPINE; CENTRAL STIMULANT AGENT; CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; DIPHENHYDRAMINE; FLUPHENAZINE; HALOPERIDOL; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; OXYBUTYNIN; QUETIAPINE; RISPERIDONE; ZIPRASIDONE; DIBENZOTHIAZEPINE DERIVATIVE; PIPERAZINE DERIVATIVE; QUINOLONE DERIVATIVE;

ADOLESCENT; ADOLESCENT DISEASE; ADULT; AGITATION; AKATHISIA; ARTICLE; CHILD; CHILDHOOD DISEASE; DRUG INDICATION; DRUG USE; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HAND TREMOR; HUMAN; MAJOR CLINICAL STUDY; MALE; MUSCLE RIGIDITY; POLYPHARMACY; PRESCRIPTION; PRIORITY JOURNAL; SIDE EFFECT; TIC; TREMOR; AGE; BASAL GANGLIA DISEASES; CHEMICALLY INDUCED; DRUG COMBINATION; FOLLOW UP; PRESCHOOL CHILD; RETROSPECTIVE STUDY;

ADOLESCENT; AGE FACTORS; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; CHILD; CHILD, PRESCHOOL; CHOLINERGIC ANTAGONISTS; DIBENZOTHIAZEPINES; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; PIPERAZINES; QUINOLONES; RETROSPECTIVE STUDIES; RISPERIDONE;

EID: 77954574311     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1M643     Document Type: Article

References (16)

1. Wonodi I, Reeves G, Carmichael D, et al. Tardive dyskinesia in children treated with atypical antipsychotic medications. Mov Disord 2007;22: 1777-82.
2. FDA/CDER resources page. Food and Drug Administration Pediatric Advisory Committee. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ PediatricAdvisoryCommittee/UCM193204.pdf (accessed 2010 Jan 23).
3. Jensen PS, Buitelaar J, Pandina GJ, Binder C, Haas M. Management of psychiatric disorders in children and adolescents with atypical antipsychotics: a systematic review of published clinical trials. Eur Child Adolesc Psychiatry 2007;16:104-20.
4. Gebhardt S, Hartling F, Hanke M, et al. Relations between movement disorders and psychopathology under predominantly atypical antipsychotic treatment in adolescent patients with schizophrenia. Eur Child Adolesc Psychiatry 2008;17:44-53. (Pubitemid 351202151)
5. Lewis R. Typical and atypical antipsychotics in adolescent schizophrenia: efficacy, tolerability, and differential sensitivity to extrapyramidal symptoms. Can J Psychiatry 1998;43:596-604. (Pubitemid 28518689)
6. Sikich L, Hamer RM, Bashford RA, Sheitman BB, Lieberman JA. A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial. Neuropsychopharmacology 2004;29:133-45.
7. Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry 2002;47:27-38.
8. Kapur S, Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry 2001;158:360-9.
9. Correll CU. Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents. J Clin Psychiatry 2008;69(suppl 4):26-36.
10. Minzenberg MJ, Poole JH, Benton C, Vinogradov S. Association of anticholinergic load with impairment of complex attention and memory in schizophrenia. Am J Psychiatry 2004;161:116-24.
11. Kane JM. Schizophrenia. N Engl J Med 1996;334:34-41.
12. Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 2003;64:663-7.
13. Perry PJ, Alexander B, Liskow B, et al. Psychotropic drug handbook. 8th ed. Baltimore, MD: Lippincott Williams & Wilkins; 2007:106-9.
14. Pierre JM. Extrapyramidal symptoms with atypical antipsychotics: incidence, prevention and management. Drug Saf 2005;28:191-208. (Pubitemid 40364887)
15. Chouinard G. Interrelations between psychiatric symptoms and drug-induced movement disorder. J Psychiatry Neurosci 2006;31:177-80.
16. Kumra S, Jacobsen LK, Lenane M, et al. Case series: spectrum of neuroleptic-induced movement disorders and extrapyramidal side effects in childhood-onset schizophrenia. J Am Acad Child Adolesc Psychiatry 1998;37:221-7.